Register Form

Please fill up the form below:

ESMO 2017

EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY ANNUAL CONGRESS 2017

  • 08 Sep 2017 to 12 Sep 2017
  • IFEMA – Feria de Madrid
  • Madrid / Spain

Whats About

Cancer has manifested itself as a bane of mankind whose treatment is not only expensive but also takes a severe toll on one’s health. In the world of internet and rapid strides made in cancer treatment, it is but logical that a platform exists where all people related in aspects of this peculiar disease come together to exchange their views and provide solution to various complexities associated with this disease. ESMO, the European Society for Medical Oncology puts before us a platform where a wide spectrum of people dealing with cancer treatment and research, spanning from lab assistants, nurses to doctors takes part. The ESMO Congress 2017 will be held in Madrid, Spain from 08 September to 12 September 2017. Being the leading organization in Oncology research in Europe, it will bring together a multifaceted diaspora dealing with cancer. It would highlight the new breakthroughs in cancer treatment, patient care, problems and their solutions thereof. This forum provides an excellent opportunity not only to address issues related to cancer but also to enhance the professional aptitude by making readily available practical experiences and exposures of leading individuals in the field of oncology. Your participation in this congress will be highly appreciated as your contributions in this field have indeed been noteworthy. Like the Spaniards fight the bull, we hope that you can help fight cancer for mankind.


Available Hotels
Hotel NameRooms AbailableFromToRatingDistanceBook Now
LEONARDO BOUTIQUE HOTEL MADRID2008-09-201712-09-2017310.5KmBook Now
LEONARDO HOTEL MADRID CITY CENTER4008-09-201712-09-2017310.2KmBook Now

Program Highlights of the Events

  • Day 1 (08 September)
  • Day 2 (09 September)
  • Day 3 (10 September)
  • Day 4 (11 September)

  • Opening session and award lectures
  • Immunotherapy: The next steps
  • Proffered Paper sessions
  • Optimal therapy in localized rectal cancer
  • Cancer stem cell properties
  • Industry Satellite Symposiums
  • What is new in germ cell tumors
  • Industry Satellite Symposium
  • Genome instability, its relevance to cancer and therapeutic potential
  • ESMO-ECAR Joint Symposium: Preclinical models for developing combination therapeutics
  • ESMO-KACO Joint Symposium: Molecular targets in breast cancer
  • WSMO-ESP Joint Symposium: The evolution of pathological reporting
  • ESMO-ASCO Joint Symposium: Evidence from single arm trials
  • Standards of diagnosis and care in brain tumors
  • ESMO-JSMO Joint Symposium: Combinations with immune-oncology agents for gastrointestinal cancer. Which ones make the best partners?
  • ESMO-ESOP Joint Symposium: The growing need for collaboration between clinicians and oncology pharmacists
  • ESMO-EONS Joint Symposium: Promoting patient safety at clinical and organizational levels
  • ESMO-WHO Joint Symposium: Workforce optimization : Results of the WHO-ESMO study on health workforce requirements for breast cancer care
  • Science and patients advocacy
  • Health services research in cancer
  • Debate: Transparency in working with Industry

 

  • Clinical implications of tumor evolution
  • Immunotherapy in thoracic malignancies: What can we expect in 2017?
  • Oligometastatic NSCLC
  • Controversial issues in the neo adjuvant approach to early breast cancer
  • Immuno-oncology in upeer GI cancer: PD1 and beyond
  • Presidential Symposium
  • Molecular targeted therapy of advanced colorectal cancer
  • CDK4 inhibitors in metastatic breast cancer
  • How to manage ovarian cancer in 2017
  • Pancreatic cancer
  • Poster Discussion session
  • Predictive biomarkers for response to immune-therapy
  • Controversy session
  • Vomiting: One symptom, many causes
  • Midgut neuroendocrine tumor progressing on 1st line somatostatin analog: What treatment approach?
  • Lymph involvement in GU cancer
  • Management of toxicities
  • Brain progression on targeted therapies and immune-therapies
  • Access to novel targeted therapies and clinical trials in Europe
  • Immuno-therapy and targeted therapies in lymphomas
  • ESMO-ESTRO Joint Symposium: Lung cancer: Research development of multimodal treatments
  • Germline aberrations and prostate cancer
  • ESMO-IPOS Joint Symposium: Working together to prevent professional burnout and improve patient care
  • ESMO-SIOPE Joint Symposium: Tumors at the edge of paediatric adult oncology: Emphasising collaboration
  • Multimodality therapy of early stage mesothelioma
  • Adjuvant systematic therapy in STS and GIST for whom?
  • Women 4 Oncology
  • Clinical cases of solid tumors: discussion forum for practicing and young oncologists
  • Communicating with cancer patients in the era of personalized medicine
  • Bio-ethical approach and harmonization across the EU
 

  • Optimal treatment of RAS mutated patients
  • How to manage luminal breast cancer
  • Coping with escalating healthcare costs in 2017 and beyond
  • Proffered paper session
  • Optimising treatment of metastatic prostate cancer
  • Industry satellite symposium
  • Immuno-therapy beyond checkpoint inhibitors
  • ESMO-EFFORT-EACR Joint Symposium: Tumors with rare oncogenic lesion, from pre- clinical to clinical validation
  • Precision medicine for metastatic breast cancer
  • Presidential Symposium
  • Poster discussion sessions
  • State of the art pf melanoma therapy
  • Management of locally advanced gastric and oesophageal adenocarcinoma
  • Complications and toxicities: Tips for daily practice
  • Innovative therapies in head and neck cancer
  • Immuno-therapy in head and neck cancer
  • Controversy sessions
  • ESMO Clinical practice guideline
  • Locoregional challenges with neo adjuvant systematic therapy
  • Oligomestatic disease: Immunotherapy and /or local treatment
  • ESMo-CSCO Joint Symposium: Liquid biopsy in the clinic. From myth to reality
  • Treating patients with melanoma brain metastases
  • GE Junction tumors
  • Multidisciplinary management of localized high risk bladder cancer
  • Challenges and complex presentations: Non resectable bone sarcoma
  • How to conciliate the fat moving genetic landscape with everyday practice and resources
  • Chalenges and oppurtunities in the treatment of Hodgkin’s lymphoma
  • Recent advances in endocrine malignancies
  • Patient outcomes research
  • Burn out in young oncologist: How we combat it?
  • Secondary MDS and AML
  • The “macro-economics” of cancer
  • Young oncologists and excellence in clinical research: ESMO YOC meets Methods in Clinical Cancer Research Workshop- MCCR
  • Rare cancers

  • Proffered paper sessions
  • Challenges in oncogene addicted NSCLC
  • Does Immunotherapy cure advanced cancer?
  • Impact of tumor heterogeneity on precision medicine in kidney and bladder cancers
  • Immuno-biology in prostate cancer
  • Industry satellite symposium
  • Presidential Symposium
  • Management of brain metastases
  • Cancer evolution and metastasis: From single cells to population dynamics
  • Update on new therapies for triple negative breast cancer (TNBC)
  • Treatment of young women with breast cancer
  • Poster discussion sessions
  • Are grade III/IV toxicities the only ones that matter?
  • Treating your patients using epigenetics
  • Emerging topics in developmental therapeutics
  • B cell receptor as a therapeutic agent
  • Neuroendocrine neoplasms of the gastro-enteropancreatic system: From the bench to the bed
  • Lung cancer screening
  • Emergency topics in developmental therapeutics
  • Clinical challenges in head and neck cancer
  • Do we need to test for PD-L1 and how do we choose?
  • Access to innovative drugs in the EU
  • Management of MO patient with rising PSA
  • Hpw to best mange ologometastatic disease
  • ESMO-ESOI Hoint Symposium: Colerectal cancer imaging-New opportunities to guide treatment decisions
  • The “Micro Economics” of cancer. How the medical oncologist should micro-manage limited resources
  • Management of MO patient with rising PSA
  • The new EU clinical trials and data protection regulations
  • Management of typical and atypical lung neuroendocrine tumors
  • Critically ill cancer patients: Patient selection for admission to ICU
  • Fellowships in Europe: educational oppurtunities for young oncologists
  • The HANS KEULEN MEMORIAL DEBATE
  • Your choice of career path in oncology